

DOCKET NO.: ISIS0052-100 (ISPH-0622)

PATENT

In the Claims:

The present listing of claims will replace all prior versions and listings of claims in the application.

Please cancel claim 9.

Please cancel claims 12-50 without prejudice to their presentation in another application, as being drawn to non-elected inventions.

Please amend claims 1 and 5, and add new claims 51-59 as follows.

Claim 1 (currently amended) An antisense compound 8 to 30 nucleobases in length targeted to the 5' untranslated region, ~~ending region, intron/exon junction, intron region, exon region,~~ translation termination codon region or 3' untranslated region of a nucleic acid molecule encoding human mdm2 (SEQ ID NO:1), wherein said antisense compound modulates the expression of mdm2.

Claim 2 (original) The antisense compound of claim 1 wherein said antisense compound inhibits the expression of human mdm2.

Claim 3 (original) The antisense compound of claim 1 which is an antisense oligonucleotide.

Claim 4 (canceled)

Claim 5 (currently amended) The antisense compound of claim 2 wherein the nucleic acid molecule encoding mdm2 is the S-mdm2 transcript, and wherein the antisense compound which is targeted to the 5' untranslated region of the S-mdm2 transcript.

Claim 6 (original) The antisense compound of claim 1 which contains at least one phosphorothioate intersugar linkage.

DOCKET NO.: ISIS0052-100 (ISPII-0622)**PATENT**

Claim 7 (original) The antisense compound of claim 1 which has at least one 2'-O-methoxyethyl modification.

Claim 8 (original) The antisense compound of claim 1 which contains at least one 5-methyl cytidine.

Claim 9 (cancelled)

Claim 10 (original) A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 11 (original) The pharmaceutical composition of claim 10 wherein said pharmaceutically acceptable carrier or diluent further comprises a lipid or liposome.

Claims 12-50 (cancelled)

Claim 51 (new) The antisense compound of claim 7 wherein at least one 2'-O-methoxyethyl modification is in a cytidine.

Claim 52 (new) The antisense compound of claim 51 in which every 2'-O-methoxyethyl modified cytidine is a 5-methyl cytidine.

Claim 53 (new) An antisense compound 8 to 30 nucleobases in length targeted to the coding region or exon region of a nucleic acid molecule encoding mdm2, wherein said antisense compound is a chimeric phosphorothioate oligonucleotide comprising 2'-methoxyethyl wings and a deoxy gap, and wherein said antisense compound inhibits mdm2 expression by at least 60%.

Claim 54 (new) The antisense compound of claim 53 wherein said antisense compound inhibits the expression of human mdm2.

DOCKET NO.: ISIS0052-100 (ISPH-0622)

PATENT

Claim 55 (new) The antisense compound of claim 53 which comprises at least one 5-methyl cytidine.

Claim 56 (new) The antisense compound of claim 53 wherein at least one 2'-methoxyethyl modification is in a cytidine.

Claim 57 (new) The antisense compound of claim 56 in which every 2'-methoxyethyl modified cytidine is a 5-methyl cytidine.

Claim 58 (new) A pharmaceutical composition comprising the antisense compound of claim 53 and a pharmaceutically acceptable carrier or diluent.

Claim 59 (new) The pharmaceutical composition of claim 58 wherein said pharmaceutically acceptable carrier or diluent further comprises a lipid or liposome.